NYSE · TEVA
Teva Pharmaceutical Industries Limited
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TEVA: Nov 03, 2026
Teva Pharmaceutical Industries Limited Ordinary Shares is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $0.7. The reported EPS for the same quarter last year was $0.75.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.70 | $0.73 | $0.65 | 4 |
| Dec 2026 | $0.78 | $0.96 | $0.68 | 5 |
| Mar 2027 | $0.62 | $0.63 | $0.61 | 3 |
| Jun 2027 | $0.70 | $0.73 | $0.67 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · BNK Invest · RTTNews- Zacks · Oct 29, 8:15 AM EDTWhat Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 EarningsGet a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
- The Motley Fool · Oct 25, 7:05 AM EDTWhere Will Neurocrine Biosciences Be in 5 Years?Ingrezza remains Neurocrine's biggest revenue driver, with sales growing 15%.
- BNK Invest · Oct 23, 11:01 AM EDTSPDW, SPOT, TEVA, SE: ETF Inflow AlertLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have detected an approximate $314.9 million dollar inflow — that's a 0
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- Fintel · Oct 22, 9:57 PM EDTTeva Pharmaceutical Industries Limited – Depositary Receipt Price Target Decreased by 19.30% to $0.11The average one-year price target for Teva Pharmaceutical Industries Limited – Depositary Receipt (NYSE:TEVA) has been revised to $0.11 / share from $0.13 on October 1, 2026, a decrease of 19.30%. These figures represent aggregate analyst targets compiled by Fintel and do not con
- RTTNews · Oct 20, 12:00 PM EDTTeva, Sanofi Report Sustained Duvakitug Benefits In Phase 2b IBD Study(RTTNews) – Teva Pharmaceutical Industries Ltd. (TEVA) and Sanofi (SNY) announced positive long-term Phase 2b data for investigational duvakitug, showing sustained improvements in ulcerative colitis (UC) and Crohn's disease (CD) through Week 44 of the RELIEVE UCCD long-term exten
- RTTNews · Oct 16, 3:02 PM EDTFDA Drug Approvals In September 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) approved 13 drugs in September 2026, spanning first-in-class therapies, treatments for rare diseases, and new options for patients with serious conditions.With the month yielding a mix of new therapies and expanded treatment
- RTTNews · Oct 16, 10:55 AM EDTWeekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) – This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.
- RTTNews · Oct 16, 1:19 AM EDTMayne Pharma Agrees To Settle IMVEXXY Patent Litigation With Teva Pharmaceutical(RTTNews) – On Friday, Mayne Pharma Group Ltd., (MYX.AX) said it has agreed to settle U.S. patent litigation with Teva Pharmaceuticals USA (TEVA) concerning IMVEXXY, its estradiol vaginal inserts for treating moderate to severe dyspareunia due to menopause.
- BNK Invest · Oct 14, 10:47 AM EDTNoteworthy ETF Inflows: EFA, SPOT, TEVA, SELooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI EAFE ETF (Symbol: EFA) where we have detected an approximate $310.4 million dollar inflow — that's a 0.4% increase week over week in ou
- Zacks · Oct 13, 9:57 AM EDTJ&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock DownJNJ beats Q3 earnings estimates but misses sales expectations as MedTech lags. It raises its 2026 sales and earnings outlook.
- Zacks · Oct 12, 11:07 AM EDTTEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in SchizophreniaTeva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Teva Pharmaceutical Industries Limited from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.